Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the Company’s latest internal review of the current available safety data for its ongoing multi-center Phase 2 trial of NX-1207 has revealed no serious drug side effects. NX-1207 is Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH).
